$MDT

Do Wall Street Analysts Like Medtronic Stock?

Analysts covering Medtronic (MDT) expect fiscal-year EPS for the year ending April 2027 to rise 7.4% to $5.94. The stock has beaten consensus EPS in each of the last four quarters. Of 29 analysts, consensus is “Moderate Buy” with 15 “Strong Buy” ratings. UBS upgraded MDT to “Buy” with a $100 target; mean target is $96.81 and Street-high is $120.

Original reporting
Published Aug 5, 2026, 11:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Do Wall Street Analysts Like Medtronic Stock? — source image
Decision brief

The 30-second read

$MDTBullishLow
01

Why it matters

This is primarily a sentiment and positioning update for MDT, reflecting how analysts are framing the next fiscal year EPS growth and recent earnings beats.

02

Market read

Traders may use the upgrade and target dispersion as a short-term sentiment input, but there is no new operational or financial disclosure.

03

What to watch

The piece does not detail the upgrade thesis or any updated fundamentals, so traders may overestimate the durability of the bullish targets.

Relevance 4/10Novelty 4/10Timing: as of the latest analyst-rating update (published Aug 5)

Background

The article summarizes sell-side consensus for Medtronic and highlights a recent UBS upgrade and price targets.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

UBS upgraded Medtronic to a Buy and set a $100 price target, with the article citing upside versus current levels.

Expected impact

Near-term support from upgrade-driven flows is plausible, but the move is likely sentiment-driven rather than fundamental.

Evidence & confidence

The article provides concrete rating and target changes (UBS upgrade, Street-high target), but no new company fundamentals like earnings, guidance, trials, or contracts.

Market effects

Could modestly lift sentiment across medical devices, but the article is single-name analyst-target focused.

No clear regional spillover beyond US-listed MDT coverage.

Limited, since the catalyst is an analyst action rather than a global regulatory or product event.

Counterpoint

Analyst upgrades can fade quickly if they are not tied to new earnings, guidance, or trial/product catalysts.

Key entities

  • Medtronic

    Subject of the article, with consensus rating, EPS expectations, and a UBS upgrade with a $100 target.

Related articles

$MDTMed

Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

Medtronic (NYSE: MDT) said it expanded the CE Mark indication for its Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, including ventricular tachycardia and PVCs. Medtronic also reported FDA Breakthrough Device Designation for Sphere-9 and that the U.S. Sphere VT pivotal trial is enrolling patients.

$MDTMed

Etowah Co. couple awarded $88 million in landmark hernia mesh verdict

A federal jury in Massachusetts awarded Alabama couple Larry and Tammy Patterson $88 million in a hernia mesh case against Covidien, a Medtronic subsidiary. The jury found Covidien failed to adequately warn about risks of its Symbotex mesh. Larry received $77 million and Tammy $11 million. The verdict was the first federal bellwether in a multidistrict litigation with over 2,500 pending suits.

$MDTMedAI 8/10

Medtronic Ordered to Pay $88 Million in First Hernia Mesh Test Trial

A federal jury ordered Medtronic to pay $88 million to an Alabama man and his wife in the first hernia mesh test trial. The case alleged Medtronic’s Covidien division failed to warn about risks of its Symbotex implanted mesh used in 2017. Medtronic said it will seek post-trial relief and appeal, while about 10,350 plaintiffs remain in similar litigation.

$MDTMed

Medtronic faces $88 million verdict in hernia mesh trial

A federal jury ordered Medtronic (NYSE:MDT) to pay $88 million to an Alabama couple in the first hernia mesh trial tied to implants made by its Covidien unit. The jury found Covidien failed to adequately warn of risks, and no punitive damages or fraud were awarded. Medtronic said it will seek post-trial motions and appeal.